A Phase II Single-arm Study of AMG 386 in Combination With Docetaxel for Advanced Urothelial Carcinoma After Failure of a Platinum-containing Regimen

Trial Profile

A Phase II Single-arm Study of AMG 386 in Combination With Docetaxel for Advanced Urothelial Carcinoma After Failure of a Platinum-containing Regimen

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2014

At a glance

  • Drugs Trebananib (Primary) ; Docetaxel
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Apr 2014 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 24 Dec 2013 Planned initiation date changed from 1 Dec 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
    • 31 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top